First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B-Reference-Cited by-同舟云学术

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B

Published:2016-09 Issue:3 Volume:65 Page:483-489
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Blank Antje,Markert Christoph,Hohmann Nicolas,Carls Alexandra,Mikus Gerd,Lehr Thorsten,Alexandrov Alexander,Haag Mathias,Schwab Matthias,Urban Stephan,Haefeli Walter E.

Funder

DZIF

Publisher

Elsevier BV

Subject

Hepatology

Reference35 articles.

1. EASL clinical practice guidelines: management of chronic hepatitis B virus infection;J Hepatol,2012

2. Chronic hepatitis B;Lok;Hepatology,2007

3. Chronic hepatitis B: Advances in treatment;Santantonio;World J Hepatol,2014

4. New advances in chronic hepatitis B;Tujios;Curr Opin Gastroenterol,2012

5. Effectiveness of hepatitis B treatment in clinical practice;Scaglione;Gastroenterology,2012

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting NTCP for liver disease treatment: A promising strategy;Journal of Pharmaceutical Analysis;2024-09

2. Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice;Journal of Lipid Research;2024-08

3. Liposomal nano-carriers mediated targeting of liver disorders: mechanisms and applications;Journal of Liposome Research;2024-07-10

4. Bulevirtide monotherapy in patients with chronic HDV needs further evaluation;Journal of Hepatology;2024-07

5. Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies;Journal of Hepatology;2024-06